118 related articles for article (PubMed ID: 32974181)
1. Case Report: Concomitant Diagnosis of Plasma Cell Leukemia in Patient With JAK2 Positive Myeloproliferative Neoplasm.
Kurian CJ; Thomas C; Houtmann S; Klumpp T; Binder AF
Front Oncol; 2020; 10():1497. PubMed ID: 32974181
[TBL] [Abstract][Full Text] [Related]
2. JAK2 V617F mutation, multiple hematologic and non-hematologic processes: an association?
Liu KG; Verma A; Derman O; Kornblum N; Janakiram M; Braunschweig I; Battini R
Biomark Res; 2016; 4():19. PubMed ID: 27777768
[TBL] [Abstract][Full Text] [Related]
3. JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.
Aynardi J; Manur R; Hess PR; Chekol S; Morrissette JJD; Babushok D; Hexner E; Rogers HJ; Hsi ED; Margolskee E; Orazi A; Hasserjian R; Bagg A
Br J Haematol; 2018 Jul; 182(1):78-85. PubMed ID: 29767839
[TBL] [Abstract][Full Text] [Related]
4. A rare atypical chronic myeloid leukemia BCR-ABL1 negative with concomitant
Gao T; Yu C; Xia S; Liang T; Gu X; Liu Z
Ther Adv Hematol; 2020; 11():2040620720927105. PubMed ID: 32782768
[TBL] [Abstract][Full Text] [Related]
5. Acute promyelocytic leukemia co-existing with JAK2 V617F positive myeloproliferative neoplasm: a case report.
Mamorska-Dyga A; Wu J; Khattar P; Ronny FM; Islam H; Seiter K; Liu D
Stem Cell Investig; 2016; 3():8. PubMed ID: 27358900
[TBL] [Abstract][Full Text] [Related]
6. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
[TBL] [Abstract][Full Text] [Related]
7. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
8. Myeloproliferative Neoplasm or Reactive Process? A Rare Case of Acute Myeloid Leukemia and Transient Posttreatment Megakaryocytic Hyperplasia with JAK-2 Mutation.
Wang S; Yan J; Zhou G; Heintzelman R; Hou JS
Case Rep Hematol; 2016; 2016():6054017. PubMed ID: 27752371
[TBL] [Abstract][Full Text] [Related]
9. Protracted Clonal Trajectory of a
Langabeer SE; Haslam K; Smyth MA; Quinn J; Murphy PT
Case Rep Hematol; 2018; 2018():8713020. PubMed ID: 29854499
[TBL] [Abstract][Full Text] [Related]
10. Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms.
Lee E; Lee KJ; Park H; Chung JY; Lee MN; Chang MH; Yoo J; Lee H; Kong SY; Eom HS
Ann Lab Med; 2018 Mar; 38(2):147-154. PubMed ID: 29214759
[TBL] [Abstract][Full Text] [Related]
11. JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN).
Kodali S; Chen C; Rathnasabapathy C; Wang JC
Leuk Res; 2009 Dec; 33(12):e236-9. PubMed ID: 19625083
[TBL] [Abstract][Full Text] [Related]
12. Polycythemia Vera.
Spivak JL
Curr Treat Options Oncol; 2018 Mar; 19(2):12. PubMed ID: 29516275
[TBL] [Abstract][Full Text] [Related]
13. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis.
Shimizu T; Kubovcakova L; Nienhold R; Zmajkovic J; Meyer SC; Hao-Shen H; Geier F; Dirnhofer S; Guglielmelli P; Vannucchi AM; Feenstra JD; Kralovics R; Orkin SH; Skoda RC
J Exp Med; 2016 Jul; 213(8):1479-96. PubMed ID: 27401344
[TBL] [Abstract][Full Text] [Related]
14. Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN with RS-T) complicated by hyperleukocytosis and gene analysis in relation to leukocytosis.
Aoyama Y; Sakai K; Kodaka T; Tsunemine H; Nishio K; Itoh T; Inoue D; Takahashi T
J Clin Exp Hematop; 2019 Mar; 59(1):29-33. PubMed ID: 30726782
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status.
Medinger M; Skoda R; Gratwohl A; Theocharides A; Buser A; Heim D; Dirnhofer S; Tichelli A; Tzankov A
Br J Haematol; 2009 Jul; 146(2):150-7. PubMed ID: 19466975
[TBL] [Abstract][Full Text] [Related]
16. Coexistence of breakpoint cluster region-Abelson1 rearrangement and Janus kinase 2 V617F mutation in chronic myeloid leukemia: A case report.
Shi XB; Jiang JF; Jin FX; Cheng W
World J Clin Cases; 2019 May; 7(9):1087-1092. PubMed ID: 31123683
[TBL] [Abstract][Full Text] [Related]
17. Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations.
Turakhia SK; Murugesan G; Cotta CV; Theil KS
J Clin Pathol; 2016 Aug; 69(8):713-9. PubMed ID: 26754830
[TBL] [Abstract][Full Text] [Related]
18. Polycythemia vera: scientific advances and current practice.
Tefferi A; Spivak JL
Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
[TBL] [Abstract][Full Text] [Related]
19. Differences in the JAK2 and MPL mutation status in the cell lineages of the bcr/abl-negative chronic myeloproliferative neoplasm subtypes.
Toyama K; Karasawa M; Yokohama A; Mitsui T; Uchiumi H; Saitoh T; Handa H; Murakami H; Nojima Y; Tsukamoto N
Intern Med; 2011; 50(21):2557-61. PubMed ID: 22041356
[TBL] [Abstract][Full Text] [Related]
20. Validation of the revised 2008 WHO diagnostic criteria in 75 suspected cases of myeloproliferative neoplasm.
Kondo T; Okuno N; Naruse H; Kishimoto M; Tasaka T; Tsujioka T; Matsuoka A; Sugihara T; Tohyama Y; Tohyama K
Leuk Lymphoma; 2008 Sep; 49(9):1784-91. PubMed ID: 18661406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
